ALN-HTT02 for Huntington's Disease
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment ALN-HTT02 for Huntington's Disease?
Research shows that reducing the levels of the huntingtin protein, which ALN-HTT02 aims to do, has been beneficial in animal models of Huntington's Disease, improving motor and cognitive symptoms. Similar treatments that lower huntingtin protein levels have shown promise in early human trials, suggesting potential benefits for ALN-HTT02.12345
Is ALN-HTT02 safe for humans?
How is the drug ALN-HTT02 different from other treatments for Huntington's Disease?
ALN-HTT02 is unique because it targets the underlying cause of Huntington's Disease by reducing the levels of the mutant huntingtin protein, which is responsible for the disease's progression. This approach is different from other treatments that mainly address symptoms rather than the root cause.145910
What is the purpose of this trial?
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose of ALN-HTT02.
Research Team
Medical Director
Principal Investigator
Alnylam Pharmaceuticals
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Double-blind Treatment
Participants receive a single dose of either ALN-HTT02 or placebo
Open-label Treatment
Participants have the option to receive a single dose of ALN-HTT02
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ALN-HTT02
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alnylam Pharmaceuticals
Lead Sponsor
Dr. Yvonne Greenstreet
Alnylam Pharmaceuticals
Chief Executive Officer since 2021
MD from the University of Leeds, MBA from INSEAD
Dr. Pushkal Garg
Alnylam Pharmaceuticals
Chief Medical Officer since 2016
MD from Columbia University